MX2021005801A - Metodos para administrar corticosteroides. - Google Patents
Metodos para administrar corticosteroides.Info
- Publication number
- MX2021005801A MX2021005801A MX2021005801A MX2021005801A MX2021005801A MX 2021005801 A MX2021005801 A MX 2021005801A MX 2021005801 A MX2021005801 A MX 2021005801A MX 2021005801 A MX2021005801 A MX 2021005801A MX 2021005801 A MX2021005801 A MX 2021005801A
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- administering
- urinary
- methods
- corticosteroids
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title abstract 3
- 229960001334 corticosteroids Drugs 0.000 title abstract 2
- AODPIQQILQLWGS-UHFFFAOYSA-N (3alpa,5beta,11beta,17alphaOH)-form-3,11,17,21-Tetrahydroxypregnan-20-one, Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 AODPIQQILQLWGS-UHFFFAOYSA-N 0.000 abstract 4
- 230000002485 urinary effect Effects 0.000 abstract 4
- SYGWGHVTLUBCEM-UHFFFAOYSA-N (3alpha,5alpha,17alphaOH)-3,17,21-Trihydroxypregnane-11,20-dione Natural products C1C(O)CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 SYGWGHVTLUBCEM-UHFFFAOYSA-N 0.000 abstract 2
- AODPIQQILQLWGS-FDSHTENPSA-N 5a-Tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@H]21 AODPIQQILQLWGS-FDSHTENPSA-N 0.000 abstract 2
- 101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 abstract 2
- SYGWGHVTLUBCEM-ZIZPXRJBSA-N Urocortisone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 SYGWGHVTLUBCEM-ZIZPXRJBSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- AODPIQQILQLWGS-GXBDJPPSSA-N tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 AODPIQQILQLWGS-GXBDJPPSSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769932P | 2018-11-20 | 2018-11-20 | |
| PCT/US2019/046449 WO2020106337A1 (en) | 2018-11-20 | 2019-08-14 | Methods for administering corticosteroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005801A true MX2021005801A (es) | 2021-08-05 |
Family
ID=70774135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005801A MX2021005801A (es) | 2018-11-20 | 2019-08-14 | Metodos para administrar corticosteroides. |
| MX2025002836A MX2025002836A (es) | 2018-11-20 | 2021-05-17 | Metodos para administrar corticosteroides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002836A MX2025002836A (es) | 2018-11-20 | 2021-05-17 | Metodos para administrar corticosteroides |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12220412B2 (https=) |
| EP (1) | EP3883578A4 (https=) |
| JP (2) | JP7472122B2 (https=) |
| CN (1) | CN113329754A (https=) |
| AU (2) | AU2019384074B2 (https=) |
| BR (1) | BR112021009653A2 (https=) |
| CA (1) | CA3120339A1 (https=) |
| IL (2) | IL283069B2 (https=) |
| MX (2) | MX2021005801A (https=) |
| WO (1) | WO2020106337A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022076398A1 (en) * | 2020-10-07 | 2022-04-14 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| CA3124945A1 (en) | 2018-12-27 | 2020-07-02 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| BR112021015481A2 (pt) * | 2019-02-08 | 2021-12-07 | Sanofi Sa | Otimização biotecnológica de micro-organismos para a 1,2-desidrogenação de esteroides |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US12310981B2 (en) | 2021-05-10 | 2025-05-27 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| WO2023225507A1 (en) * | 2022-05-16 | 2023-11-23 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
| EP4525983A4 (en) * | 2022-05-16 | 2025-09-03 | Sparrow Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS |
| AU2024348222A1 (en) * | 2023-09-27 | 2026-04-16 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid-mediated diseases |
| GB202408335D0 (en) | 2024-06-11 | 2024-07-24 | Astrazeneca Ab | Therapies for wound treatment |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3907821A (en) | 1974-11-20 | 1975-09-23 | Upjohn Co | 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone |
| US4577020A (en) | 1983-01-25 | 1986-03-18 | The Upjohn Company | Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents |
| IL84093A (en) | 1986-10-09 | 1992-09-06 | Ciba Geigy Ag | Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them |
| GB0101447D0 (en) * | 2001-01-19 | 2001-03-07 | Univ Edinburgh | Regulation of glucocorticoid concentration |
| GB0107383D0 (en) | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
| AUPR878201A0 (en) | 2001-11-09 | 2001-12-06 | Fujisawa Pharmaceutical Co., Ltd. | New compounds |
| WO2003059267A2 (en) | 2001-12-21 | 2003-07-24 | Rhode Island Hospital | SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF |
| WO2003065983A2 (en) | 2002-02-01 | 2003-08-14 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| ATE467616T1 (de) | 2003-04-11 | 2010-05-15 | High Point Pharmaceuticals Llc | Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase |
| US20060094699A1 (en) * | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| WO2004089367A1 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| DE602004025220D1 (de) | 2003-04-11 | 2010-03-11 | High Point Pharmaceuticals Llc | Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen |
| US8026264B2 (en) | 2003-05-29 | 2011-09-27 | Merck Sharp And Dohme Corp. | Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1 |
| AU2004286836A1 (en) | 2003-10-28 | 2005-05-19 | Amgen Inc. | Triazole compounds and uses related thereto |
| JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
| AP2006003633A0 (en) | 2003-12-19 | 2006-06-30 | Pfizer | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity |
| US7507832B2 (en) | 2003-12-22 | 2009-03-24 | Eli Lilly And Company | Triazole PPAR modulators |
| AU2005230864A1 (en) | 2004-03-29 | 2005-10-20 | Merck Sharp & Dohme Corp. | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US8022225B2 (en) | 2004-08-04 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd | Triazole derivative |
| JP4882748B2 (ja) | 2004-09-16 | 2012-02-22 | アステラス製薬株式会社 | トリアゾール誘導体またはその塩 |
| JP2008518903A (ja) | 2004-11-02 | 2008-06-05 | ファイザー・インク | 置換および非置換アダマンチルアミドの新規化合物 |
| WO2006068199A1 (ja) | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体 |
| WO2006080533A1 (ja) | 2005-01-31 | 2006-08-03 | Mochida Pharmaceutical Co., Ltd. | ３－アミノ－１,２,４－トリアゾール誘導体 |
| WO2006134481A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
| CN101198605A (zh) | 2005-06-16 | 2008-06-11 | 辉瑞大药厂 | N-(吡啶-2-基)-磺酰胺衍生物 |
| AU2006257646A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | N-(pyridin-2-YL)-sulfonamide derivatives |
| WO2007007688A1 (ja) | 2005-07-08 | 2007-01-18 | Mochida Pharmaceutical Co., Ltd. | ３,５－ジアミノ－１,２,４－トリアゾール誘導体 |
| JP5261176B2 (ja) | 2005-08-16 | 2013-08-14 | アイカジェン， インコーポレイテッド | 電位作動型ナトリウムチャンネル阻害剤 |
| AR058807A1 (es) | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
| BRPI0708782A2 (pt) | 2006-03-16 | 2011-06-14 | Astellas Pharma Inc | derivado de triazol ou um sal deste |
| US20070224298A1 (en) | 2006-03-23 | 2007-09-27 | Talbott Shawn M | Inhibiting 11(beta)-hsd1 with citrus flavonoids |
| US7435833B2 (en) | 2006-04-07 | 2008-10-14 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| WO2010001946A1 (ja) | 2008-07-03 | 2010-01-07 | アステラス製薬株式会社 | トリアゾール誘導体またはその塩 |
| EP2243494A1 (en) * | 2009-04-22 | 2010-10-27 | OntoChem GmbH | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. |
| WO2011068927A2 (en) * | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| UA112418C2 (uk) * | 2010-09-07 | 2016-09-12 | Астеллас Фарма Інк. | Терапевтичний болезаспокійливий засіб |
| SG11201405214YA (en) * | 2012-03-13 | 2014-10-30 | Abbvie Inc | Method for selecting or identifying a subject for v1b antagonist therapy |
| CN106659723A (zh) * | 2014-07-09 | 2017-05-10 | 爱普制药有限责任公司 | 用于治疗神经病症的方法 |
| US10894054B2 (en) | 2015-04-07 | 2021-01-19 | Intercept Pharmaceuticals, Inc. | FXR agonist compositions for combination therapy |
| US10648506B2 (en) | 2016-07-07 | 2020-05-12 | Raul Mendoza | Walking rig creeper interface |
| WO2018117063A1 (ja) | 2016-12-20 | 2018-06-28 | アステラス製薬株式会社 | 焦燥性興奮治療剤 |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| EP3821892A1 (en) | 2019-11-12 | 2021-05-19 | University of Leeds | (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds |
| EP3878446A1 (en) | 2020-03-09 | 2021-09-15 | Universite De Geneve | Hsd11b1 inhibitors for use in immunotherapy and uses thereof |
| EP4525983A4 (en) | 2022-05-16 | 2025-09-03 | Sparrow Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS |
| WO2023225507A1 (en) | 2022-05-16 | 2023-11-23 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
-
2019
- 2019-08-14 CN CN201980076112.6A patent/CN113329754A/zh active Pending
- 2019-08-14 EP EP19886299.7A patent/EP3883578A4/en active Pending
- 2019-08-14 CA CA3120339A patent/CA3120339A1/en active Pending
- 2019-08-14 US US17/289,516 patent/US12220412B2/en active Active
- 2019-08-14 IL IL283069A patent/IL283069B2/en unknown
- 2019-08-14 BR BR112021009653-1A patent/BR112021009653A2/pt unknown
- 2019-08-14 IL IL319327A patent/IL319327A/en unknown
- 2019-08-14 MX MX2021005801A patent/MX2021005801A/es unknown
- 2019-08-14 AU AU2019384074A patent/AU2019384074B2/en active Active
- 2019-08-14 JP JP2021525303A patent/JP7472122B2/ja active Active
- 2019-08-14 WO PCT/US2019/046449 patent/WO2020106337A1/en not_active Ceased
-
2021
- 2021-05-17 MX MX2025002836A patent/MX2025002836A/es unknown
-
2024
- 2024-04-10 JP JP2024063590A patent/JP2024098991A/ja active Pending
- 2024-12-13 US US18/980,242 patent/US20250205227A1/en active Pending
-
2025
- 2025-04-30 AU AU2025203033A patent/AU2025203033A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL283069B2 (en) | 2025-09-01 |
| EP3883578A4 (en) | 2022-07-27 |
| CA3120339A1 (en) | 2020-05-28 |
| JP2024098991A (ja) | 2024-07-24 |
| MX2025002836A (es) | 2025-04-02 |
| WO2020106337A1 (en) | 2020-05-28 |
| IL283069B1 (en) | 2025-05-01 |
| JP2022507103A (ja) | 2022-01-18 |
| JP7472122B2 (ja) | 2024-04-22 |
| IL319327A (en) | 2025-05-01 |
| US12220412B2 (en) | 2025-02-11 |
| EP3883578A1 (en) | 2021-09-29 |
| AU2019384074A1 (en) | 2021-06-03 |
| US20250205227A1 (en) | 2025-06-26 |
| US20210393622A1 (en) | 2021-12-23 |
| IL283069A (en) | 2021-06-30 |
| BR112021009653A2 (pt) | 2021-08-17 |
| AU2025203033A1 (en) | 2025-05-22 |
| AU2019384074B2 (en) | 2025-04-10 |
| CN113329754A (zh) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005801A (es) | Metodos para administrar corticosteroides. | |
| CL2020002919A1 (es) | Inhibidores de mcl-1 | |
| BR112022022401A2 (pt) | Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade | |
| CR20190350A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| EP4424364A3 (en) | Methods of treating liver disease | |
| CR20210373A (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| MX2020003959A (es) | Metodos terapeuticos relacionados con los inhibidores de hsp90. | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| MX388408B (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv | |
| AR061350A1 (es) | Regimen extendido de reduccion progresiva de estrogenos | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| MX2022008479A (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CO2023013397A2 (es) | Compuestos de tienopirrol | |
| CO2021015622A2 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| MX2019002259A (es) | Inhibicion de la actividad de la olig2. | |
| MX2021015970A (es) | Terapia de combinacion con bloqueo de semaforina-4d (sema4d) y terapia de dc1. | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
| AR116417A1 (es) | COMBINACIONES DE INHIBIDORES DE TGFb E INHIBIDORES DE CDK PARA TRATAMIENTOS CONTRA EL CÁNCER |